Northwire Canada EditionTuesday, July 28, 2026
Sign inSubscribe
Northwire
⌕
LUG 81.27 +2.4% ETG 2.65 +1.1% ARIC 0.860 +2.4% ABC 0.020 +0.0% WEC 0.010 +0.0% NTB 0.020 +0.0% URC 3.83 −8.2% BEX 0.085 +6.2% SUM 1.32 +0.0% FMN 0.270 +10.2% PHNM 0.405 +12.5% HDRO 1.11 −6.7% PWM 0.620 −1.6% LIO 0.155 +10.7% NTH 0.160 +1.6% ELEF 0.120 −4.0% LUG 81.27 +2.4% ETG 2.65 +1.1% ARIC 0.860 +2.4% ABC 0.020 +0.0% WEC 0.010 +0.0% NTB 0.020 +0.0% URC 3.83 −8.2% BEX 0.085 +6.2% SUM 1.32 +0.0% FMN 0.270 +10.2% PHNM 0.405 +12.5% HDRO 1.11 −6.7% PWM 0.620 −1.6% LIO 0.155 +10.7% NTH 0.160 +1.6% ELEF 0.120 −4.0%
Other

HEALWELL's DARWEN(TM) AI Platform Demonstrates One of the World's First Examples of Using AI to Generate Regulatory-Grade Real-World Data (RWD) for Supporting Patient Access and Advancing the Pharmaceutical Industry

By The Northwire Desk — AI Analysis Oct 21, 2025 · 03:16 AIDX · 1.38 HEALWELL AI INC. J CL A SV
AIDX · Price

Executive Summary

  • HEALWELL AI announced that its DARWEN™ AI platform generated regulatory‑grade real‑world data (RWD) showing that vedolizumab dose escalation (8 weeks → 4 weeks) improves remission outcomes in ulcerative colitis and Crohn’s disease.
  • The results were presented at United European Gastroenterology (UEG) Week in Berlin on October 6, 2025 in collaboration with Takeda Pharmaceutical.
  • HEALWELL was named a finalist for Newsweek’s inaugural AI Impact Awards 2025, highlighting its leadership in healthcare AI.

Key Details

  • Collaboration: HEALWELL AI + Takeda Pharmaceutical (top‑20 global pharma).
  • Presentation Venue & Date: United European Gastroenterology (UEG) Week, Berlin – October 6, 2025.
  • AI Platform: DARWEN™ AI platform generated the RWD/RWE.
  • Therapeutic Focus: Vedolizumab dose escalation for ulcerative colitis and Crohn’s disease.
  • Clinical Insight: Switching dosing from every 8 weeks to every 4 weeks produced improved remission outcomes, supporting potential label advancement and broader patient access.
  • Disease Burden Context: Inflammatory bowel disease affects ~2.39 million people in the U.S. and ~400,000 in Canada (cited sources).
  • Scientific Validation: DARWEN™ AI platform has >40 peer‑reviewed manuscripts validating its capability for clinical data abstraction and RWD/RWE generation.
  • Recognition: Finalist in Newsweek’s 2025 AI Impact Awards for advancing validated, ethical AI with measurable clinical/commercial impact.

Notable Quotes

“Our collaboration with Takeda demonstrates how our DARWEN™ AI platform can unlock clinically meaningful insights from the wealth of data buried and not effectively used within electronic health records and documents,” – Dr. Christopher Pettengell, Chief Medical Officer, HEALWELL AI.

“AI is reshaping our world, and the organizations receiving this award are at the forefront of that transformation,” – Jennifer H. Cunningham, Editor‑in‑Chief, Newsweek.

Read the original news release →

More from HEALWELL AI INC. J CL A SV

Jun 17, 2026 · 12:10

AI pilot progress and a $25M SpaceX stake offer a bright spot, but the shares’ slide and lock-up delay temper enthusiasm.

Other May 07, 2026 · 16:01

HEALWELL’s revenue explodes 316% and cash piles up, but a skeptical market keeps the stock pinned near its lows—doubting the AI narrative without a path to true net profit.

Earnings Mar 19, 2026 · 07:01

HEALWELL AI Delivers Record Revenue and First Year of Positive Adjusted EBITDA as Global AI Platform Strategy Takes Hold

Earnings Mar 12, 2026 · 14:12

Healwell talks Darwen AI peer-reviewed publications

Other Mar 12, 2026 · 03:16

HEALWELL AI Reaches 47 Peer-Reviewed Publications, Strengthening Its Scientific Moat for AI-Powered Real-World Clinical Evidence Generation

Production / Operations Mar 09, 2026 · 14:58

Healwell AI to release 2025 results March 19

Earnings